Robert G Strickley

This inventor holds 12 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Gilead Sciences, Inc., Amygdala Neurosciences, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert G Strickley. Retrieved from https://idiyas.com/inventor/robert-g-strickley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 6)

% Patents Active = 83.3

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 64(Granted Patents)

Location History:

Foster City, CA (US) (2018)
San Mateo, CA (US) (2013 - 2024)

Company Filing History:

10 out of 946

Gilead Sciences, Inc.

patents

2 out of 5

Amygdala Neurosciences, Inc.

patents

Years Active: 2013-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12202849 - Crystalline forms of tenofovir alafenamide (2025-01-21),

2. 11975017 - Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections (2024-05-07),

3. 11440928 - Crystalline forms of tenofovir alafenamide (2022-09-13),

4. 11266681 - Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections (2022-03-08),

5. 10507215 - Compounds for the treatment of addiction (2019-12-17),

6. 10287307 - Crystalline forms of tenofovir alafenamide (2019-05-14),

7. 10039718 - Use of solid carrier particles to improve the processability of a pharmaceutical agent (2018-08-07),

8. 9987295 - Compounds for the treatment of addiction (2018-06-05),

9. 9610299 - Compounds for the treatment of addiction (2017-04-04),

10. 9000015 - Compounds for the treatment of addiction (2015-04-07),

11. 8575353 - Compounds for the treatment of addiction (2013-11-05),

12. 8558001 - Compounds for the treatment of addiction (2013-10-15),

Title: The Innovative Contributions of Robert G. Strickley

Introduction

Robert G. Strickley is a prominent inventor based in San Mateo, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for viral infections. With a total of 12 patents to his name, Strickley's work has had a substantial impact on medical science.

Latest Patents

Among his latest patents is the invention related to crystalline forms of tenofovir alafenamide. This invention focuses on novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, along with pharmaceutical formulations and therapeutic uses for treating viral infections. Another notable patent involves compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections. This disclosure provides a composition that includes Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.

Career Highlights

Strickley has worked with several esteemed companies throughout his career, including Gilead Sciences, Inc. and Amygdala Neurosciences, Inc. His work in these organizations has allowed him to collaborate on groundbreaking research and development projects.

Collaborations

Some of his notable coworkers include Carina E. Cannizzaro and Michael Graupe. Their collaborative efforts have contributed to the advancement of innovative solutions in the pharmaceutical industry.

Conclusion

Robert G. Strickley exemplifies the spirit of innovation in the field of pharmaceuticals. His contributions through patents and collaborations have paved the way for new treatments that address critical health challenges.

Profile summary based on public USPTO records.